Opinion|Videos|January 3, 2025
Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Panelists discuss how recent trials evaluating quadruplet regimens in transplant-ineligible/deferred NDMM, including IMROZ and BENEFIT, demonstrate promising efficacy with isatuximab-VRd combinations showing comparable MRD negativity rates to CEPHEUS’ daratumumab-VRd data, though cross-trial comparisons require careful interpretation.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please comment on other quadruplet regimens in the TIE or deferred NDMM space.
- Briefly discuss IMROZ(isatuximab [Isa]-VRd vs VRd)
- IMROZ, MRD negativity
- Briefly discuss BENEFIT (Isa-VRd vs Isa-Rd)
- Thinking back to CEPHEUS, how do data from these trials compare?
Advertisement
Related to this article
Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.
The EMA validated the marketing authorization application for varegacestat in adults with desmoid tumors.
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
P. Leia Nghiemphu, MD, discusses INTUITT-NF2 trial findings, the NCCN inclusion of brigatinib, and unmet needs in NF2-related schwannomatosis.
NEXERA-303 is evaluating INCA33890 plus FOLFOX and bevacizumab vs chemotherapy and bevacizumab alone in previously untreated MSS mCRC.
Biagio Ricciuti, MD, PhD, discusses Krascendo 1 data for divarasib, co-mutation–guided sequencing, and emerging RAS inhibitors in KRAS G12C–positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
RELATIVITY-1093 Trial Aims to Advance Nivolumab Plus Relatlimab and Chemo in Nonsquamous NSCLC
2
Dostarlimab Monotherapy Elicits Durable cCRs in dMMR/MSI-H Locally Advanced Rectal Cancer
3
NEXERA-303 Trial Aims to Bring TGFβR2×PD-1 Bispecific Antibody INCA33890 Into First-Line MSS CRC
4
The OncFive: Top Oncology Articles for the Week of 10/25
5